| Dec'17 | ||||||
|---|---|---|---|---|---|---|
Operating expenses: | ||||||
Research and development, net of participations | ||||||
5,416 | ||||||
Marketing, general and administrative | ||||||
1,407 | ||||||
Total operating expenses | ||||||
6,823 | ||||||
Operating loss | ||||||
-6,823 | ||||||
Financial income | ||||||
5 | ||||||
Financial expense | ||||||
3,148 | ||||||
Loss | ||||||
-9,966 | ||||||
Other comprehensive income (loss): | ||||||
Items to be reclassified to profit or loss in subsequent periods: | ||||||
Gain (loss) from available-for-sale marketable securities | ||||||
-2 | ||||||
Total comprehensive loss | ||||||
-9,968 | ||||||
Basic and diluted loss per share | ||||||
-0.05 | ||||||
Weighted average number of shares outstanding used to compute basic and diluted loss per share | ||||||
201,030 | ||||||